Zeria Pharmaceutical
As of the edition of 20 October 2026, Zeria Pharmaceutical runs 12 drugs, 6 of them marketed; it is on route A at 0 targets and on route B at 4 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 6 |
| Went quiet | 5 |
| Stopped | 1 |
| Total | 12 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Budesonide | Ends 2029 (exclusivity) | 5 |
| Ferric carboxymaltose | Ends 2027 (patent) | 0 |
| Mesalamine | Ends 2027 (patent) | 12 |
| Acotiamide | none listed | 0 |
| Sodium phosphate, monobasic | none listed | 0 |
| Patiromer sorbitex calcium | Ends 2030 (patent) | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 4 targets.
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where Zeria Pharmaceutical needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 4 trials led
- Blood and lymph: 3 trials led
- Digestive system: 3 trials led